Concentration and Activity of Lapatinib in Vestibular Schwannomas
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Tumors can grow on the auditory nerves and can cause hearing loss. A common type of tumor
that does this is a vestibular schwannoma (VS), or acoustic neuroma. These tumors are not
cancerous. Most often, people have only one VS. Occasionally, people have more than one VS
and may have a condition called neurofibromatosis type 2 (NF2).
Because VS can cause hearing loss, many people with VS will have treatment to preserve their
hearing. This treatment usually involves surgery or radiation therapy. There are risks to
these procedures, and sometimes they do not work to prevent hearing loss. Because surgery and
radiation have risks and are not able to help everyone with VS, other methods of treatment
are being explored. One area of exploration is looking to see if there is a drug that can be
taken that might prevent the VS from growing larger and causing hearing loss, and might
possibly even cause the VS to shrink in size.
This study is exploring whether a drug that is approved by the FDA and is currently used to
treat breast cancer might also work to treat VS. This study will measure the amount of drug
that travels from the bloodstream and arrives at the tumor. This drug is safe and has few
side effects. If this drug is shown to reach the tumor, it might be used in the future to
treat VS without needing surgery or radiation.
This study is recruiting people who are having surgery for VS. If you are going to have
surgery to treat a VS, you may be eligible to participate.
Phase:
Early Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
GlaxoSmithKline House Research Institute Massachusetts General Hospital New York University Ohio State University The Children's Tumor Foundation Washington University School of Medicine Weill Medical College of Cornell University